Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | GRK2 | P25098 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 6/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CDK1 | P06493 | 4/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | CDC7 | O00311 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | MARK3 | P27448 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14514018 | 0.87 | CA1 (0.54) | ROCK2GRK2GSK3BCDK2CDK1 | |
| SCHEMBL3825878 | 0.82 | ROCK2 (0.48) | ROCK2GRK2CDK2CDK1ROCK1 | |
| SCHEMBL5383599 | 0.81 | ADORA2A (0.62) | ROCK2GSK3BCDK2CDK1ROCK1 | |
| SCHEMBL5400018 | 0.81 | NCOA1 (0.63) | ROCK2GSK3BCDK2CDK1ROCK1 | |
| SCHEMBL3850720 | 0.80 | CA12 (0.55) | CDK2CLK4CLK2DYRK1AADORA2A | |
| SCHEMBL14514019 | 0.80 | GSK3B (0.59) | ROCK2GSK3BCDK2CDK1ROCK1 | |
| SCHEMBL5380322 | 0.78 | PDE4B (0.58) | ROCK2GSK3BCDK2CDK1ROCK1 | |
| SCHEMBL3825028 | 0.77 | XDH (0.51) | ROCK2GRK2GSK3BCDK2CDK1 | |
| SCHEMBL7524252 | 0.75 | CDK1 (0.69) | GSK3BCDK2CDK1CDK7CDK9 | |
| SCHEMBL14513942 | 0.73 | KDM4E (0.47) | MAPK1ADORA2AMTORCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585482-A4 | NOUVELLES COMPOSITIONS ET METHODES DE TRAITEMENT DU PSORIASIS | GENENTECH INC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-1578371-A4 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH INC (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1578996-A4 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH INC (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1572116-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | GENENTECH INC (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070117818-A1 | Pyrimidinone compounds useful as kinase inhibitors | HASEGAWA MASAICHI | 2007-05-24 | — | — | US | disclosed |
| US-20070117818-A1 | Pyrimidinone compounds useful as kinase inhibitors | HASEGAWA MASAICHI | 2007-05-24 | — | — | US | disclosed |
| EP-1696963-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN | Genentech, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1694864-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1608967-A4 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH INC (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1494709-A4 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH INC (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1114152-A2 | SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME | Genentech, Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000053757-A2 | PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION | GENENTECH, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000053752-A2 | PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION | GENENTECH, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000053756-A2 | SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME | GENENTECH, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000053754-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000053755-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000053751-A1 | METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH | GENENTECH, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000039297-A2 | IL-1 RELATED POLYPEPTIDES | GENENTECH, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000037638-A2 | METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH | GENENTECH, INC. (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000015796-A2 | SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME | GENENTECH, INC. (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117818-A1 | Pyrimidinone compounds useful as kinase inhibitors | HIPK3, HIPK1, HIPK2 | ROCK2 432/4885GRK2 486/4885GSK3B 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.